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Abstract Inducible heat shock protein (HspA1A) promotes
tumor cell growth and survival. It also interacts with effector
cells of the innate immune system and affects their activity.
Recently, we showed that the direct contact of ovarian cancer
cells, isolated from tumor specimens, with neutrophils inten-
sified their biological functions. Our current experiments
demonstrate that the activation of neutrophils, followed by
an increased production of reactive oxygen species, by cancer
cells involves the interaction of HspA1A from cancer cells
with Toll-like receptors 2 and 4 expressed on the neutrophils’
surface. Our data may have a practical implication for targeted
anticancer therapies based, among other factors, on the inhi-
bition of HspA1A expression in the cancer cells.
Keywords Heat shock protein . Toll-like receptors .
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Introduction
Mammalian heat shock proteins (Hsp) have been classified
into five families, according to their molecular size. The
Hsp70 family includes, among others, heat inducible Hsp70i
(HspA1A), formerly known as Hsp72, and constitutively
expressed Hsc70 (HspA8) proteins (Kampinga et al. 2009).
Intracellularly located HspA1A mainly participates in the
maintenance of cellular homeostasis during stress conditions
such as heat, hypoxia, ischemia, acidosis, and energy deple-
tion. It is also known that HspA1A is secreted from dead and
living cells and exerts a powerful effect on the immune system
(Kregel 2002; Daugaard et al. 2007). HspA1A is released
from necrotic cells via a passive mechanism or from living
cells via an active mechanism involving the translocation of
protein through the lysosomal compartment, using the ABC
family of transmembrane transporters (Mambula and
Calderwood 2006; Asea 2007a; Mambula et al. 2007). The
released HspA1A, by being bound with the various immune
cells, participates in the inflammatory and immune responses.
It also induces the production of pro-inflammatory cytokines,
binds the antigenic peptides, and stimulates the adaptive im-
mune response, as well as enhances the expression of MHC
class II on dendritic cells, which in turn allows its maturation
(Asea et al. 2002; Calderwood et al. 2007a, 2005). HspA1A
interacts with target cells via a number of cell surface recep-
tors, e.g., CD91, CD36, CD40, and Toll-like receptors (TLRs)
2 and 4 or other c-type lectin receptors (Calderwood et al.
2007b; Theriault et al. 2005).
TLR2 and TLR4 are type 1 transmembrane proteins that
belong to the family of pattern recognition receptors. The
signaling pathway induced via TLRs is a multistep process
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that may or may not depend on MyD88 adapter protein
pathways. An adapter protein, MyD88, binds to a receptor
Toll/IL-lR-domain and interacts with protein kinases of
the IRAK family (e.g., interleukin-1 receptor-associated
kinases—IRAK1, IRAK4), which leads to the phosphoryla-
tion of the target signaling proteins, including mitogen-
activated protein kinases, phosphoinositide 3-kinase, nuclear
factor-κB (NF4-κB), and AKT (also known as protein kinase
B) (Chen et al. 2007; Krishnan et al. 2007).
Numerous reports demonstrate that basal levels of
HspA1A, both in a serum and in a tumor microenvironment
of patients with various cancers (breast, lung, prostate, co-
lorectal, pancreatic), often correlate with poor survival and
response to chemotherapy of patients (Abe et al. 2004;
Suzuki et al. 2006; Zhang et al. 2009; Sherman and
Multhoff 2007; Aghdassi et al. 2007). HspA1A located
intracellularly seems to be necessary for cancer cell growth
and survival. It protects cancer cells from oxidative stress,
hypoxia, and inflammatory cytokines and blocks the apo-
ptotic pathways in cells (Garrido et al. 2006; Daugaard et al.
2005). On the other hand, HspA1A is highly expressed on
the cell surface of tumor cells, but not on normal cells, as an
integral membrane-bound protein that can be uniquely iden-
tified by cmHsp70.1 monoclonal antibody (Sherman and
Multhoff 2007; Multhoff and Hightower 2011). HspA1A
is also secreted into extracellular space (Kleinjung et al.
2003; Schmitt et al. 2007; Asea 2007b). HspA1A located
extracellularly, as well as when membrane-bound, can trigger
the activity of immune cells and initiate an immune response.
It was found that cancer cells demonstrating membrane-bound
HspA1A stimulated the migration and cytolytic activities of
natural killer cells (Asea 2007b; Botzler et al. 1996; Gastpar et
al. 2005; Multhoff and Hightower 1996). Among the immune
cells that interact with cancer cells are polymorphonuclear
cells (neutrophils). As others have shown, cytotoxic media-
tors, such as reactive oxygen species (ROS), released from
neutrophils, could not only mediate the tumor cells lysis (Di
Carlo et al. 2001; Lichtenstein et al. 1989; Lopez-Lazaro
2007) but could also promote tumor progression (De Larco
et al. 2004).
We found previously that the ovarian cancer cells, isolated
from the tumors of patients with advanced stage ovarian
cancer, enhanced the production of ROS by autologous pe-
ripheral blood neutrophils (Klink et al. 2008). However, the
molecules, receptors, etc. which mediate this interaction have
not yet been pointed out. The aim of this study was to examine
whether HspA1A membrane-bound and/or released from
ovarian cancer cells could be involved in the activation of
neutrophils of patients with advanced ovarian cancer. The
participation of TLR2 and TLR4 expressed on neutrophils in
the interaction via HspA1Awith ovarian cancer cells was also
investigated.
Materials and methods
Chemical reagents and antibodies
Histopaque 1077, Percoll, phorbol 12-myristate 13-acetate
(PMA), formyl-methionyl-leucyl-phenylalanine (fMLP),
bovine serum albumin (BSA), propidium iodide (PI), di-
methyl sulfoxide (DMSO), Triton X100, mouse IgG2a
anti-β actin, horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG, IgA, IgM, NaF, EGTA, EDTA, NaCL,
phenylmethylsulfonyl fluoride (PMSF), sodium orthovana-
date, protease inhibitor cocktail, Tris, sodium dodecyl sulfate
(SDS), β-mercaptoethanol, glycerol, glycine, bromophenyl
blue, methanol, polyethylene glycol 3500 (PEG 3500),
Tween 20, and IRAK1/4 inhibitor were purchased from
Sigma-Aldrich (USA). Luminol was obtained from Serva
(Germany). DC Protein Assay Kit, 30 % acrylamide/Bis-
37.5:1, polyvinylidene difluoride (PVDF) membrane, and
Precision Plus WesternC standard were purchased from
BioRad (USA). Dextran T500 was obtained from
Pharmacosmos A/S (Denmark). Purified human recombinant
Hsp72 (hrHsp72) was purchased from Stressgen (USA).
Phosphate-buffered saline (PBS) was obtained from
BIOMED-Lublin (Poland). Hanks’ balanced salt solution
(HBSS), RPMI 1640 supplemented with 2 mM of glutamine,
and 0.25 % Trypsin solution with EDTA (Trypsin–EDTA
solution) were purchased from PAA, the Cell Culture
Company (Austria). Antibodies mouse IgG2a anti-human
TLR2 sodium azide free, mouse IgG2a anti-human TLR4
sodium azide free, mouse IgG2a anti-TLR2 PE-conjugated,
and mouse IgG2a anti-TLR4 FITC conjugated were obtained
from Imgenex (USA). Mouse IgG1 anti-human Hsp72
(SPA810) andmouse anti-humanHsp72 (SPA810) FITCwere
purchased from Stressgen (USA). Antibody to Epithelial Cell
Adhesion Molecule (EpCAM) FITC-conjugated was pur-
chased from Miltenyi Biotec GmbH (Germany). Mouse
IgG1 monoclonal antibody cmHsp70.1 FITC conjugated
was obtained from Multimmune, (Germany). Hsp70 ELISA
Kit was purchased from Stressgen (USA). BD CellFIX solu-
tion was obtained from BD Biosciences Pharmingen (USA).
Patients
This study included patients suffering from advanced epithe-
lial ovarian cancer (International Federation of Gynecology
and Obstetrics (FIGO) III/IV). The patients had undergone the
primary surgery for ovarian cancer in the Gynecologic
Surgery Department and Operative Gynecology Department
of the Polish Mother’s Memorial Hospital—Research
Institute, Lodz, Poland. The patients’ ages ranged from 35 to
70 years, and the ovary was a primary site of malignancy for
all the women. All tissue samples removed during the surgery
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were examined by a pathologist, and the tumor grade and its
histological type were established according to the FIGO and
WHO classification (Benedet et al. 2000). None of the patients
received any chemo- or radiotherapy before the surgery. The
control group consisted of 10 age-matched healthy female
volunteers.
Cell lines description
Ovarian cancer cell lines of epithelial morphology and adher-
ent growth type were used. SK-OV-3 and OVCAR-3 cell lines
were purchased from the American Type Culture Collection
(Manassas, VA, USA). A2780 cell line was obtained from the
European Collection of Cell Cultures (Porton Down,
Salisbury, UK). Cells were cultured in a culture medium
(CM) containing RPMI 1640 medium supplemented with
2 mM glutamine and 10 % fetal bovine serum at 37 °C and
in a 5 % CO2 atmosphere. CM renewal was every 2 to 3 days,
and cells were passaged two to three times a week, trypsinized
using Trypsin–EDTA solution at 37 °C and in a 5 % CO2
atmosphere.
Isolation of neutrophils
Peripheral venous blood from cancer patients was taken on the
day of surgery, before the surgical procedure. Blood samples
from the cancer patients and the control group were centri-
fuged on Histopaque 1077 (400×g, 30 min, room tempera-
ture). Mononuclear cells were collected and saved. Remaining
plasma and gradient material were aspirated down to the
erythrocytes interface. Cell pellets, containing erythrocytes
and neutrophils, were resuspended in PBS to the initial whole
blood volume. Next, red blood cells were allowed to sediment
for 30 min at room temperature by the addition of equal
amounts of 3 % Dextran T500. The neutrophil-rich superna-
tant was centrifuged (500×g, 10 min), and neutrophils’ pellet
was washed twice with PBS without Ca+2 andMg+2 ions. The
remaining erythrocytes that contaminate the neutrophils’ pel-
let were lysed with NH4Cl lysing solution. Finally, cells were
resuspended in HBSS buffer. Neutrophil viability (>95%) and
cell purity (>98 %) were assessed by Trypan blue exclusion
and May–Grünwald–Giemsa staining, respectively.
Isolation of ovarian cancer cells
Ovarian cancer tissue was collected during the surgery from
the primary site. Ovarian cancer (OC) cells were obtained as
described previously (Klink et al. 2008). Briefly, fragments
of tumor specimens were rubbed by using the Cell
Dissociation Sieve—Tissue Grinder Kit (Sigma) directly to
PBS. Then, cells were washed three times with PBS (300×g,
10 min, 4 °C) and were filtered using Filcon disposable filter
device (BD Biosciences, USA). Finally, cells were layered
on a discontinuous Percoll gradient (60, 50, 40, and 30 %)
and then centrifuged (500×g, 30 min, room temperature) to
remove the contaminating leukocytes and red blood cells.
Interface 0 (between the PBS and 30 % Percoll) contained
>95 % pure tumor cells. The OC cells were washed twice
with PBS and resuspended in HBSS. The cytocentrifugal
preparations of OC cells were prepared, and the purity of
cells was assessed by a hematoxylin–eosin histological and
a leukocyte common antigen staining. To confirm the epi-
thelial origin of cancer cells and for their separation from
other cell types, cells were labeled with anti-EpCAM FITC
antibody. EpCAM expression on tumor cells was detected
by flow cytometry method (FCM). OC cell viability was
determined using a PI exclusion assay.
Flow cytometry
Surface expression of TLR2, TLR4, and membrane-bound
HspA1A was assessed by flow cytometry. Freshly isolated
neutrophils (2×106 cells/ml in HBSS) were incubated with
20 μg/ml of anti-TLR2 and anti-TLR4, sodium azide-free,
blocking monoclonal antibodies (mAbs) for 30 min, at room
temperature or remained untreated. Then, cells were stimu-
lated or not with 1 μg/ml of PMA or 1 μM of fMLP for
30 min at 37 °C in a 5 % CO2 atmosphere. Placing all
samples on ice stopped the reaction and cells were then
stained with anti-TLR2 PE-conjugated and anti-TLR4
FITC-conjugated mAbs or with 10 μl of appropriate isotype
control for 30 min at 4 °C in the dark.
OC cells were stained with cmHsp70.1 FITC-conjugated
mAbs that recognize membrane-bound HspA1A (Multhoff
and Hightower 2011), according to the Multimmune GmbH
procedure or with anti-EpCAM FITC-conjugated mAbs for
30 and 10 min, respectively, at 4 °C in the dark. All samples
were fixed with BD CellFIX solution and stored at 4 °C
until the analysis on a Beckman Coulter (USA) flow cytom-
eter equipped with Cytomics FC 500 MPL System with
MXP Software for cell acquisition and data analysis. The
neutrophils and OC cells were gated on the forward and side
scatter (FSC versus SSC). The expression of membrane-
bound HspA1A was measured in viable (PI-negative) and
dead (PI-positive) cells. The results were presented as me-
dian fluorescence intensity (MFI), which correlates with the
expression of the surface molecule. MFI was determined by
subtracting the MFI of untreated cells (isotype) from the
MFI of positive-stained cells with the appropriate mAbs.
Detection of released HspA1A
OC cells (1×105 in HBSS) were distributed into 96-well
plates, and 1 μg/ml of PMA or 1 μM of fMLP was added or
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not into the wells and cells were then incubated for 60 min at
37 °C in a 5 % CO2 atmosphere. The incubation time was
adjusted to the time of OC cell–neutrophil interaction during
ROS production. PMA and fMLP were added to verify
whether these stimulators could affect the OC cells to re-
lease HspA1A. Plates were centrifuged (250×g, 10 min) and
supernatants were collected and stored at −85 °C. In a
separate experiment, three cell lines (A2780, SK-OV-3,
and OVCAR-3) were cultured for 72 h in 24-well plate
(106 cells/well) in the CM. After that, culture supernatants
were collected and stored at −85 °C. The quantitative anal-
ysis of HspA1A in supernatants was performed by ELISA
assay using an appropriate Hsp72 ELISA kit with the sen-
sitivity of 200 pg/ml. The presence of HspA1A in the super-
natants was also detected with western blot analysis
(described below). Supernatants were obtained from cell
lines and OC cells. The culture contained from 1.2×106 to
1.8×106 cell/ml.
Western blot analysis
OC cells from tumors (5×106 cells in HBSS) were lysed for
30 min on ice in the lysis buffer containing 1 % Triton X-
100, 20 mM Tris, 150 mM NaCL, pH 7.4, and supple-
mented with 1 mM PMSF, 5 mM NaF, 2 mM sodium
orthovanadate, 1 mM EGTA, 1 mM EDTA, and 1 % prote-
ase inhibitor cocktail. A2780, SK-OV-3, and OVCAR-3 cell
lines were cultured for 72 h in 24-well plates (106 cells/
well). Then, cells were removed from plates using Trypsin–
EDTA solution, centrifuged, suspended in HBSS (5×
106 cells/ml), and lysed as described above. The protein
concentration in the lysates was determined using a DC
Protein Assay Kit. The collected supernatants (as described
earlier) and lysates were mixed up 1:1 with 2× SDS–poly-
acrylamide gel electrophoresis (PAGE) sample buffer
(125 mM Tris, pH 6.8, 4 % SDS, 2 % β-mercaptoethanol,
20 % glycerol, 0.02 % bromophenol blue) and boiled for
5 min. Samples containing an equal amount of protein were
run on 10 % SDS–PAGE minigel. The proteins were trans-
ferred to PVDF membranes for 18 h at 4 °C at 35 mA.
Membranes were blocked using 0.5 % BSA and 1 % PEG
3500 in 2× TBS–Tween (25 mM Tris, 190 mM NaCL,
10 mM NaF, 0.2 % Tween 20) for 2 h. Then, membranes
were incubated with mouse IgG1 anti-inducible form of
Hsp72 (SPA810) or with mouse IgG2a anti-β actin mono-
clonal antibodies for 2 h at room temperature and washed
five times in 2× TBS–Tween. Afterward, membranes were
incubated with HRP-conjugated goat anti-mouse IgG, IgA,
and IgM (1:1,000 in blocking buffer) for 1 h and again
washed five times in 2× TBS–Tween. HspA1A and β-
actin bands were visualized using the enhanced chemilumi-
nescence (CL) system (Santa Cruz Biotechnology, USA).
Actin expression was used as an internal (loading) control.
Densitometric analysis of the visualized bands was per-
formed using FluoroChem MultiImage FC Cabinet (Alpha
Innotech Corporation) and Alpha Ease FC software 3.1.2.
The results were presented as the optical density intensity of
the area under each band’s peak (ODI).
ROS production
The production of ROS molecules by neutrophils was
assessed with a luminol-enhanced CL method. Neutrophils
(2×106 cells/ml in HBSS) were treated with 20 μg/ml of
anti-TLR2 and anti-TLR4 sodium azide-free blocking mAbs
for 30 min at room temperature or with a 10 μM of specific
inhibitor of IRAK1 and IRAK4 kinases (IRAK1/4 inhibitor)
for 30 min at 37 °C or remained untreated. Afterward, 50 μl
of neutrophils’ suspension (1×105 cells/well) and 25 μl of
OC cells suspension (1×105 cells/well) were distributed into
96-well plates and co-incubated for 30 min (37 °C, 5 %
CO2). Subsequently, 1 μg/ml of PMA or 1 μM of fMLP to
initiate the ROS production and 10 μM of luminol to en-
hance CL were added to cells.
In the separate experiments, neutrophils after pre-treatment
or not with inhibitor IRAK1/4 were distributed into 96-well
plates and incubated with exogenous human recombinant
HspA1A (hrHspA1A; 5 ng or 10 ng/ml) for 30 min (37 °C,
5 % CO2). Next, the production of ROS in neutrophils was
induced as described above. In separate experiments, 50 μl of
neutrophils’ suspension (1×105 cells/well) was pre-incubated
with 25 μl OC cell supernatant (obtained as described in
“Materials and methods”) for 30 min (37 °C, 5 % CO2) and
then stimulated with PMA or fMLP (see above).
DMSO was used as a diluent to prepare fMLP and PMA
solutions and was checked for a possible stimulating effect
on neutrophils. DMSO solution prepared in HBSS, at the
final concentrations of 0.1 %, did not affect ROS production
by neutrophils over basal levels (in comparison to unstimu-
lated cells in HBSS buffer). The values of RLU total in
neutrophils in the presence of the diluent at concentrations
used were included in the figures.
The CL reading was recorded for 30 min, with 2-min
intervals, on a Fluoroscan Ascent FL fluorometer (Labsystem,
Finland). CL intensity was given in relative light units (RLU).
Data were expressed as RLU total values, calculated as the
area under the curve of CL versus assay time.
Interaction of hrHspA1A with TLR2 and TLR4
Interaction of hrHspA1A with TLR2 and TLR4 on human
neutrophils was determined by FCM. Neutrophils (2×106)
from healthy individuals were pre-incubated or not with
20 μg/ml of anti-TLR2 and anti-TLR4, sodium azide-free,
664 M. Klink et al.
blocking mAbs for 30 min, and next, cells were incubated
with or without hrHspA1A (250 ng/ml, 30 min, 37 °C, 5 %
CO2). Afterward, neutrophils were stained with anti-human
Hsp72 (SPA810) FITC conjugated (30 min at 4 °C in the
dark) to detect the presence of receptor-bound HspA1A
(Multhoff and Hightower 2011).
In separate experiments, neutrophils were incubated with
or without exogenous 250 ng/ml of hrHspA1A or 250 ng/ml
of BSA (30 min, 37 °C, 5 % CO2). Then, cells were stained
with anti-TLR2 PE-conjugated and anti-TLR4 FITC-
conjugated mAbs or with 10 μl of appropriate isotype
control for 30 min at 4 °C in the dark. All cell samples were
fixed and analyzed as described above.
Statistical analysis
Data are presented as the mean±SD. Statistical analysis of the
TLRs expression on neutrophils of cancer patients versus a
control group was performed with a nonparametric Mann–
WhitneyU test. The statistical significance of the effect of OC
cells and hrHspA1A on neutrophils was verified with
Wilcoxon’s signed-rank test. The Statistica 8.0 (StatSoft,
Poland) software package was used for data statistical calcu-
lations. Statistical significance was defined as p≤0.05.
Results
Surface expression of TLR2 and TLR4 on neutrophils
We tested whether the effect of OC cells on neutrophils is
mediated by TLRs. The expression of TLR2 and TLR4 on
the surface of freshly isolated as well as PMA- or fMLP-
stimulated neutrophils of cancer patients versus healthy
individuals (control group) was assessed using FCM. As
shown in Fig. 1, there were no statistical differences be-
tween the expression of TLR2 and TLR4 on unstimulated
neutrophils of cancer patients and healthy donors. However,
we found that exposure of cancer patients’ neutrophils to
PMA or fMLP significantly enhanced the expression of both
types of TLRs (Fig. 1). The increase in values of TLR2 MFI
from 1.7±1.4 to 4.8±2.7 and to 3.6±3.0 and in values of
TLR4 MFI from 1.8±2.1 to 4.4±2.8 and to 3.6±2.6 was
noted, after stimulation with PMA and fMLP, respectively.
Fig. 1 Flow cytometric
analysis of TLR2 and TLR4
expression on neutrophils.
Neutrophils of cancer patients
and control group were
incubated with 1 μg/ml of
PMA, 1 μM of fMLP, or
medium with diluent (0.1 %
DMSO) for 30 min prior to
staining. a Representative
histograms show TLRs
expression on neutrophils of
cancer patient and control
group. Isotype control Ab-
stained cells are shown as bold,
gray line and untreated cells
(none) as gray histograms. Solid
lines and arrows indicate neu-
trophils treated with PMA or
fMLP. Cells in the absence of
FITC or PE are marked as an
autofluorescence. b Graph
demonstrates mean values of
the median fluorescence inten-
sity (MFI) ± SD (n015). MFI
was determined by subtracting
the MFI of isotype control Ab-
stained cells from the MFI of
positive-stained cells that had
been incubated with PMA,
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In contrast, after the same stimulation of the control group
neutrophils, only TLR4 expression was increased and MFI
values rose from 2.9±2.2 to 5.7±5.2 and to 4.3±3.2, re-
spectively. Since the expression of TLRs on cancer patients’
neutrophils after incubation with PMA and fMLP was sim-
ilar, the following experiments were carried out on PMA-
stimulated cells only. After pre-incubation of patients’ neutro-
phils with anti-TLR2 and anti-TLR4 blocking mAbs, the ex-
pression of TLR2 and TLR4 on PMA-stimulated neutrophils
was reduced, as shown by a decrease ofMFI values from 7.0±
3.6 to 3.6±1.3 and from 6.5±4.3 to 2.0±1.6, respectively.
After pre-incubation of unstimulated neutrophils with these
mAbs, the expression of TLR2 and TLR4 also decreased,
and MFI values ranged from 4.3±0.5 to 2.5±0.4 and from
4.2±1.6 to 1.6±1.4, respectively (Fig. 2). DMSO as a diluent
of fMLP and PMA does not affect the staining of TLRs (results
not shown).
Surface, extracellular, and intracellular location of HspA1A
in OC cells
In this study, we verified the hypothesis whether membrane-
bound HspA1A on OC cells or HspA1A released by them is
responsible for the activation of neutrophils during OC cell–
neutrophil interaction. Flow cytometric analysis showed that
nearly 80 % of OC cells expressed membrane-bound HspA1A
(MFI value 187±27) and EpCAM molecule (Fig. 3a, b, re-
spectively). Precise analysis also showed that among 63±14%
(47–88 %) of cells expressing the membrane-bound HspA1A,
24±8 % (12–36 %) of cells were PI negative (viable).
Fig. 2 Expression of TLR2 and
TLR4 on unstimulated and
PMA-stimulated neutrophils in
the presence of anti-TLR2 and
anti-TLR4 blocking mAbs.
Neutrophils of cancer patients
were pre-treated with 20 μg/ml
of anti-TLR2 and anti-TLR4,
sodium azide-free, blocking
mAbs for 30 min at room tem-
perature or remained untreated
(none). Next, cells were stimu-
lated or not with PMA (1 μg/
ml). Representative histograms
show TLR2 and TLR4 expres-
sion on unstimulated (left, gray-
filled histogram) and PMA-
stimulated neutrophils (right,
gray-filled). The solid black
lines represent unstimulated and
PMA-stimulated neutrophils
incubated with blocking mAbs.
The solid gray lines represent
the autofluorescence (cells in
the absence of FITC or PE).
Graph demonstrates mean
values of the median fluores-
cence intensity (MFI) ± SD
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The amount of extracellularly released HspA1A from OC
cells was estimated in supernatants collected after incuba-
tion of OC cells with or without stimuli in vitro as described
in “Materials and methods.” OC cells released a small but
detectable amount of HspA1A (2.0±2.5 ng/ml) (Fig. 3c).
The presence of PMA and fMLP did not influence the
amount of HspA1A in OC cells supernatant (2.25±1.25
and 1.98±1.88 ng/ml, respectively). For comparison,
A2780, SK-OV-3, and OVCAR-3 cell lines released below
1 ng/ml of HspA1A (0.05±0.07, 0.14±0.02, and 0.48±
0.52 ng/ml, respectively) during 72 h of culture (Fig. 3c).
Furthermore, we observed that cell lines differed significant-
ly between themselves in the amount of released heat shock
protein. The presence of HspA1A in the supernatant from
OC cells, as well as in A2780, SK-OV-3, and OVCAR-3
cell line cultures, was also documented by western blot
assays (Fig. 3d, e).
It has been reported by others that exosomes secreted
from peripheral blood cells, macrophages, dendritic cells, or
epithelia cells may provide a secretory pathway that facili-
tates the active release of specific heat shock proteins (Asea
2007a; Lancaster and Febbraio 2005;Multhoff and Hightower
1996; Vega et al. 2008). To rule out the assumption that
HspA1A is also present within exosomes derived from OC
cells and the possibility that exosomes may be mediators of
HspA1A active release from these cells, the samples of super-
natants were treated with a 1 % Triton X-100 solution. This
mild detergent solubilizes exosomes, which leads to the re-
lease of its internal content. We did not observe any differ-
ences between the levels of HspA1A detected in supernatants
Fig. 3 Surface and
extracellular expression of
HspA1A. The representative
histograms of a HspA1A and b
EpCAM expression on OC cells
are demonstrated. OC cells




mAbs for 30 and 10 min, re-
spectively, at 4 °C in the dark.
The molecules expression was
determined using FCM assay.
The gray-filled histograms rep-
resent OC cells exposed
membrane-bound HspA1A (a)
and EpCAM (b) molecules. The
solid lines (open histograms)
represent the cells in the ab-
sence of FITC (autofluores-
cence). c The amounts of
HspA1A present in the super-
natants from OC cells and from
the ovarian cancer cells lines
culture measured using ELISA
assay. The data are presented as
means ng/ml ± SD, for OC cells
(n025) and for cancer cell lines
(n03). Western blot analysis of
extracellular HspA1A released
d from OC cells and e from
ovarian cancer cell lines. Lanes:
1 A2780, 2 SK-OV-3, 3
OVCAR-3. OC supernatants
from 16 separate samples and
ovarian cancer cell line culture
supernatants from two separate
passages (as indicated) were
analyzed
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before and after the treatment of cells with 1 % Triton X-100
solution (1.03±0.3 versus 0.90±0.14 ng/ml, respectively, n0
4). This suggests that HspA1A is released from OC cells as a
free protein into the extracellular milieu and that the various
mechanisms are involved in different cell types to facilitate the
release of HspA1A (Asea 2007a). Interestingly, in our prelim-
inary experiments, we did not find any detectable release of
HspA1A by neutrophils.
The intracellular location of HspA1A was detected in OC
cells from examined tumor specimens, as well as in ovarian
cancer cell lines (Fig. 4a). However, we observed that OC
cells from various tumor samples differed in the amount of
intracellular HspA1A and values of ODI ranged from 101,896
to 340,623. Similarly, A2780, SK-OV-3, and OVCAR-3 cell
lines demonstrated intracellular HspA1A but its amount in
lysates of mentioned cell lines was smaller than in lysates of
OC cells. The ODI values of each peak, according to our
evaluation, were almost 10-fold lower in comparison to those
detected in OC cells and amounted to 14,716, 125,369, and
173,691, respectively (Fig. 4b).
Production of ROS by neutrophils in the presence of OC
cells
Both in our earlier work (Klink et al. 2008) and in our
current, we have demonstrated the interaction of OC cells
primed neutrophils to enhanced ROS production, in re-
sponse to subsequent stimulation with PMA and fMLP. In
this study, we examined whether such activation of neutro-
phils by OC cells occurred through the interaction of TLR2
and TLR4 exposed on neutrophils with released and/or
expressed HspA1A on OC cells. To assess the participation
Fig. 4 Intracellular expression
of HspA1A. OC cells from
tumors or ovarian cancer cell
lines (cultured for 72 h) were
lysed, and the intracellular
presence of HspA1A was
detected using western blot
assay, as described in
“Materials and methods.”
Representative western blot
analysis of HspA1A located (a)
in OC cells from seven
individuals and in ovarian
cancer cell lines from three and
nine passages. Lanes: 1 A2780,
2 SK-OV-3, 3 OVCAR-3. b
Densitometric analysis of
bands. The data are expressed
as the mean values of optical
density intensity of the area
under each band’s peak ± SD,
n025 for OC cells and n03 for
cell lines
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of TLRs, neutrophils were pre-treated with a saturating con-
centration of specific anti-TLR2 and anti-TLR4 blocking
mAbs (20 μg/ml) for 30 min prior to the addition of OC cells.
Pre-incubation with the mentioned mAbs led to the total inhi-
bition of OC cells’ ability to prime neutrophils, as shown by a
decrease in the ROS production. As shown in Fig. 5, the values
of RLU total decreased from 1,582±633 for neutrophils + OC
cells + PMA to 1,073±567 for neutrophils + anti-TLRs mAbs
+ OC cells + PMA. Similarly, the values of RLU total de-
creased from 259±257 for neutrophils + OC cells + fMLP to
164±152 for neutrophils anti-TLRs mAbs + OC cells + fMLP.
To compare, the values of RLU totals for PMA- and fMLP-
stimulated neutrophils were 889±448 and 97±80, respectively.
The mediating role of TLR2 and TLR4 in ROS produc-
tion by neutrophils, after pre-incubation with OC cells, was
also confirmed in the experiments, in which the signaling
molecules, such as IRAK1 and IRAK4, that are associated
with the activation of TLR2 were inhibited by its specific
inhibitor. We found that the neutrophils response to PMA
and fMLP stimulation in the presence of OC cells and
IRAK1/4 inhibitor (RLU total values were 907±479 and
117±113, respectively) corresponded with their response
observed in the absence of OC cells (RLU total values were
898±448 and 97±80, respectively).
To prove the hypothesis that HspA1A is involved in the
activation of neutrophils, two separate experiments were
carried out. In the first experiment, neutrophils were incu-
bated with hrHspA1A and in the second one with superna-
tant containing HspA1A derived from OC cells. We found
that treatment of neutrophils with exogenous hrHspA1A at
the concentration of 10 ng/ml caused a significant enhance-
ment of ROS production by neutrophils in response to
stimulation with PMA and fMLP (Fig. 6a). To confirm that
HspA1A influences neutrophils via TLR2 and TLR4, neu-
trophils were pre-treated with IRAK1/4 inhibitor prior to
incubation with exogenous hrHspA1. We demonstrated in
Fig. 5 ROS production by
neutrophils in the presence of
OC cells. Neutrophils were pre-
treated with 20 μg/ml of anti-
TLR2 or anti-TLR4 mAbs or
with IRAK1/4 inhibitor
(10 μM) for 30 min or left un-
treated. After that, neutrophils
were co-incubated with OC
cells for 30 min and then stimu-
lated with PMA, fMLP, and
HBSS with diluent (0.1 %
DMSO) or left unstimulated.
ROS production was evaluated
using the luminol-enhanced CL
assay. Data are expressed as
mean values of relative light unit
total (RLU total) ± SD, n015.
*p≤0.01, neutrophils versus
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Fig. 6b that such a treatment of cells completely protected
neutrophils against the priming effect of hrHspA1A, as
shown by a decrease in the RLU total values from 1,326±
238 for neutrophils+hrHspA1A+PMA to 1,033±212 for
neutrophils+IRAK1/4+hrHspA1A+PMA. Similarly, we
observed a decrease in RLU total values from 137±31 for
neutrophils+hrHspA1A+fMLP to 115±19 for neutrophils+
IRAK1/4+hrHspA1A+fMLP. RLU total values for neutro-
phils + PMA or fMLP were 1,155±169 and 111±18,
respectively.
We also examined whether HspA1A, derived from OC
cells, could prime the neutrophils to enhance ROS response
to stimuli. We found that the addition of OC supernatants
pre-activated neutrophils to enhance ROS production in
response to stimuli. The RLU total values enhanced from
899±488 to 1,362±588 for neutrophils treated with PMA
and from 97±79 to 201±220 for neutrophils treated with
fMLP, as shown in Fig. 7.
Interaction of HspA1A with the neutrophils TLR2
and TLR4
The interaction of HspA1A with TLR2 and TLR4 has been
described by other authors (Asea 2006; Giraldo et al. 2010).
Nonetheless, to verify the viability of our studies, the ca-
pacity of exogenous HspA1A to bind to TLR 2 and TLR4
on neutrophils was evaluated in two separate control experi-
ments by FCM. Flow cytometric analysis revealed that the
ability of hrHspA1A to bind to neutrophils was markedly
reduced, after treatment of neutrophils with mAbs blocking
TLR2 and TLR4 expression, as shown by the decrease in
the value of MFI of HspA1A expression (Fig. 8a). Data
presented in Fig. 8b also showed that when neutrophils were
incubated with hrHspA1A, the expression of TLR2 and
TLR4 was significantly decreased. To test the specificity
of the interaction of hrHspA1A with neutrophils’ TLRs, the
cells were incubated with BSA. As shown in Fig. 8b, BSA
did not influence the expression level of neutrophils’ TLRs.
Discussion
Our current and previous studies (Klink et al. 2008) dem-
onstrated that OC cells from tumor tissues of patients with
advanced ovarian cancer pre-activated autologous blood
neutrophils to enhanced ROS production, in response to
stimulation with PMA and fMLP. ROS are the important
Fig. 6 ROS production by neutrophils in the presence of hrHspA1A. a
Neutrophils were pre-incubated with exogenous HspA1A (hrHspA1A,
5 and 10 ng/ml) for 30 min and then stimulated with PMA or fMLP. b
Neutrophils were pre-treated or not with IRAK1/4 inhibitor (10 μM)
for 30 min, then incubated with hrHspA1A (10 ng/ml) for 30 min, and
stimulated with PMA or fMLP. ROS production was assessed using the
luminol-enhanced CL assay. Data are expressed as mean values of
relative light unit total (RLU total) ± SD, n06. *p≤0.05, neutrophils
versus neutrophils+hrHspA1A, Wilcoxon’s signed-rank test
Fig. 7 ROS production by neutrophils in the presence of OC cells
supernatants. OC cells were incubated in HBSS for 60 min at 37 °C in
a 5 % of CO2 atmosphere. Then, cells were centrifuged and super-
natants were collected. Neutrophils were incubated with OC cells
supernatants for 30 min prior to stimulation with PMA or fMLP.
ROS production was assessed using the luminol-enhanced CL assay.
Data are expressed as mean values of relative light unit total (RLU
total) ± SD, n09. *p≤0.05, neutrophils vs. neutrophils+hrHspA1A,
Wilcoxon’s signed-rank test
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molecules that can enhance cancer progression. They facilitate
angiogenesis and metastasis through stimulation of the vascu-
lar endothelial growth factor production (Ushio-Fukai and
Alexander 2004), as well as an activation of metalloprotei-
nases (De Larco et al. 2004). Therefore, it seems highly
probable that the appearance of ROS molecules, as a result
of neutrophils interaction with OC cells, may support cancer
progression. The mechanism responsible for the activation of
neutrophils by cancer cells remains unclear.
The main aim of our research was to recognize the molec-
ular mechanism of ovarian cancer cells action on autologous
neutrophils in respect to the interaction of HspA1Awith TLR2/
4. In this study, we have shown that membrane-boundHspA1A
was expressed on nearly 80 % of OC cells isolated from tumor
specimens of all tested ovarian cancer patients. Similarly,
Kleinjung et al. (2003) demonstrated that almost 60 % of
cancer cells isolated from head and neck tumors were
HspA1A positive. We and others (Mambula and Calderwood
2006; Gastpar et al. 2005) found that ovarian cancer cells
isolated from both tumors, as well as ovarian cancer cell lines
A2780, SK-OV-3, and OVCAR-3, released HspA1A outside
cells. We demonstrated here that OC cells and cell lines also
had intracellularly located heat shock proteins. However, can-
cer cells isolated from tumors expressed considerably higher
levels of HspA1A, in comparison to cancer cell lines. This may
be the result of unfavorable conditions that occur in the tumor
environment. The environment surrounding cancer cells is
deficient in oxygen, nutrients, and glucose but is enriched in
pro-inflammatory cytokines and cytotoxic agents that enhance
the basal level of HspA1A in tumor cells and which, on the
Fig. 8 Interaction of
hrHspA1A with TLR2 and
TLR4 on neutrophils. a
Neutrophils were pre-treated or
not with 20 μg/ml of anti-TLR2
or anti-TLR4 blocking mAbs
for 30 min and then incubated
with 250 ng/ml of hrHspA1A
for 30 min. After that they were
stained with anti-HspA1A
mAbs (SPA810-FITC). Repre-
sentative histograms show the
receptor-bound HspA1A ex-
pression on neutrophils treated
with anti-TLR blocking mAbs.
Gray-filled histograms repre-
sent receptor-bound HspA1A.
The solid black lines represent
receptor-bound HspA1A after
neutrophils incubation with
anti-TLRs mAbs; gray lines
represent autofluorescence.
Graph demonstrates the values
of median fluorescence intensi-
ty (MFI) ± SD, n03. b Neutro-
phils were pre-treated with
250 ng/ml of hrHspA1A or with
250 ng/ml of BSA for 30 min
and then stained with anti-
TLR2 or anti-TLR4 mAbs.
Representative histograms
show the TLR2 and TLR4 ex-
pression on neutrophils. Gray-
filled histograms represent
TLRs expression. The solid
black lines represent TLR ex-
pression after neutrophils incu-
bation with hrHspA1A. The
gray lines represent autofluor-
escence and expression of
TLRs after neutrophils incuba-
tion with BSA as arrows indi-
cated. Graphs demonstrate the
values of MFI ± SD of TLRs on
neutrophils, n03
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other hand, is essential to the growth and survival of cancer
cells (Weber and Kuo 2011; Wilson and Balkwill 2002;
Daugaard et al. 2005). It was shown by others that interaction
of HspA1Awith its specific surface receptors caused the acti-
vation of various signal transduction pathways resulting in the
stimulation of cells. It was also shown that binding of HspA1A
to human monocytes activated NF-κB induced a rapid intra-
cellular Ca+2 influx and production of IL-1, IL-6, and tumor
necrosis factor-α (TNF-α) (Asea et al. 2002; Asea 2006).
Among the group of receptors that can bind HspA1A, TLR2,
and TLR4 are known to initiate a signal transduction cascade
resulting in the cellular response to this heat shock protein
stimulation (Asea et al. 2002).
In this study, we found that the presence not only of OC
cells but also HspA1A released from them and exogenous
hrHspA1A led to enhanced ROS production in neutrophils in
response to further stimulation with PMA and fMLP. These
findings suggested the hypothesis that the activation of neu-
trophils by OC cells may be mediated by HspA1A derived
from OC cells. Next, we investigated whether the effect of
such an interaction of OC cells with neutrophils was mediated
by occupation of TLRs on the neutrophils’ surface.
Toll-like receptors are important molecules involved in
the initiation of neutrophil activation. Numerous studies
indicate that the activation of TLRs enhances the CD11b
molecule expression, induces the L-selectin shedding, and
stimulates the production of ROS and release of chemo-
attractants, e.g., IL-8 (Kurt-Jones et al. 2002; Sabroe et al.
2005; Hayashi et al. 2003). It has also been found that the
pre-treatment of neutrophils with TLRs agonists resulted in
a marked increase in ROS production in response to subse-
quent activation with fMLP (Sabroe et al. 2003). On the
other hand, various stimuli including IL-1β, TNF-α, granu-
locyte–macrophage colony-stimulating factor, and interferon-
γ have been shown to enhance the expression of TLRs on the
surface of neutrophils (Kurt-Jones et al. 2002; O’Mahony et
al. 2008). In agreement with other reports (Kurt-Jones et al.
2002; O’Mahony et al. 2008), we demonstrated very low
constitutive expression of both TLR2 and TLR4 on the sur-
face of neutrophils isolated from the blood of cancer patients,
as well as of the control group.We found that fMLP and PMA
significantly increased the expression of both TLR2 and
TLR4 on ovarian cancer patients’ neutrophils. In contrast to
the neutrophils of cancer patients, PMA and fMLP caused an
increase in TLR4 but not in TLR2 expression levels on the
neutrophils of the control group. This difference is probably
caused by the activation status of the cancer patients’ neutro-
phils. It has been shown that circulating neutrophils of ad-
vanced cancer patients are primed in vivo, and their response
to stimuli in vitro differs significantly from that of healthy
donors’ neutrophils (production of ROS, cytokines, expres-
sion of adhesion molecule) (Klink et al. 2008; Jablonska et al.
2005; Goddard et al. 2005).
To confirm that TLR2 and TLR4 are involved in the
stimulation of ROS production by OC cells, we studied
the signal transduction pathway that can be initiated by
these receptors. We noted that the presence of specific
anti-TLR2 and anti-TLR4 blocking antibodies, as well as
of a specific inhibitor of IRAK1 and IRAK4 signaling
molecules, prevented the enhancement of ROS production
by OC cells and/or hrHspA1A. This finding suggests that
the effect of exogenous hrHspA1A and OC cells (via re-
leased or/and membrane-bound HspA1A) on neutrophils is
connected with TLRs.
Moreover, by using flow cytometry, we demonstrated
that HspA1A bound to TLR2 and TLR4 was expressed on
neutrophils. Our data are in agreement with several reports
showing that extracellular HspA1A serves as a ligand for
TLRs (Asea 2008; Giraldo et al. 2010; Ortega et al. 2009).
Others have also documented the ability of extracellular
HspA1A to stimulate neutrophil phagocytic function via
TLR2 (Giraldo et al. 2010), as well as to induce IL-8 and
TNF-α production via TLR4 (Wheeler et al. 2009) and to
induce production of pro-inflammatory cytokines via TLR2
and TLR4 (Asea et al. 2002).
In summary, we have described that direct contact of cancer
cells isolated from tumors with neutrophils intensified their
biological functions (Klink et al. 2008). Currently, our study
demonstrates for the first time that activation of ovarian cancer
patients’ neutrophils by ovarian cancer cells is dependent on
the interaction of HspA1A originating from ovarian cancer
cells, with TLR2 and TLR4 expressed on the surface of
neutrophils. Our data may have a practical implication for
targeted anticancer therapies based, among other factors, on
the inhibition of HspA1A expression in the cancer cells. The
prevention of the pro-inflammatory activity of neutrophils,
enhanced by OC cells (via expressed HspA1A), may protect
against tumor progression and metastases.
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